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Abstract
Biallelic mutations in ECHS1, encoding the mitochondrial enoyl-CoA hydratase,
have been associated with mitochondrial encephalopathies with basal ganglia
involvement. Here, we describe a novel clinical presentation consisting of dysto-
nia-ataxia syndrome with hearing loss and a peculiar torsional nystagmus
observed in two adult siblings. The presence of a 0.9-ppm peak at MR spec-
troscopy analysis suggested the accumulation of branched-chain amino acids.
Exome sequencing in index probands identified two ECHS1 mutations, one of
which was novel (p.V82L). ECHS1 protein levels and residual activities were
reduced in patients’ fibroblasts. This paper expands the phenotypic spectrum
observed in patients with impaired valine catabolism.
INTRODUCTION
ECHS1 encodes the mitochondrial enoyl-CoA hydratase
which catalyzes the fourth degradation step of the
branched-chain amino acid (BCAA) valine but also takes
part in the beta-oxidation of short-chain fatty acids, con-
tributing to energy metabolism.1
Biallelic mutations in ECHS1 (OMIM 612677) have been
mainly associated with early-onset Leigh-like syndrome (LLS)
presenting severe progressive encephalopathy and signs of
mitochondrial dysfunction including epilepsy, optic atrophy
and hearing loss.2 Cardiac abnormalities were also observed.3
Prognosis is poor, with the mean age at death of 69 months
although patients reaching adulthood have been described.4
Additional clinical symptoms might include: cutis laxa,5
paroxysmal exercise-induced dyskinesia6 and dystonia.7
Increased serum lactate levels and elevated urinary con-
centrations of 2-methyl-2,3-dihydroxybutyrate and N-
acetyl-S-(2-carboxypropyl)cysteine have been reported.8
Reduced activities of pyruvate dehydrogenase and respira-
tory chain complexes have been linked with the accumula-
tion of acryloyl-CoA andmethacrylyl-CoA, originating from
incomplete valine catabolism.9 However, these abnormali-
ties are detectable only in a subset of severe clinical courses.
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1
PATIENTS AND METHODS
The study was approved by the institutional review board
of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico. The patients provided written informed con-
sent for all aspects of the study.
The parents (Subjects I-1 and I-2) of the two affected
siblings (II-1 and II-3) were neurologically healthy and
not related (Fig. 1A). A third sibling (II-2) did not dis-
play any sign of neurological involvement. Both probands
were born late preterm after an uneventful pregnancy.
Subject II-1 presented early motor delay with difficulty
in fine motor skills, unstable gait, and frequent falls.
Mild speech delay was present and was attributed to
congenital sensorineural hearing loss. From the age of
4 years, she developed a permanent nystagmus. Motor
deficits presented a slowly progressive course. The
patient had normal intelligence and she graduated from
college. She presented at our hospital at the age of
32 years, showing a prominent unceasing torsional nys-
tagmus (Video S1) associated with hypoacusia, cerebellar
dysarthria, dysmetria, and widespread moderate to severe
increase in the muscular tone of the four limbs, and
bilateral Babinski sign. An unsteady dystonic-ataxic gait
was observed.
Subject II-3 displayed a normal psychomotor develop-
ment. Hypoacusia was present since birth. At the age of
5 years, a permanent torsional nystagmus appeared. Intel-
ligence was normal and she graduated from college. She
presented at our hospital at the age of 24 years, presenting
with unceasing torsional nystagmus. Associated clinical
features were mild cerebellar dysarthria, mild dysmetria,
intermittent dystonic movement of the left foot, and bilat-
eral Babinski sign. Mobility was normal, although the tan-
dem gait test was performed with difficulty.
In both probands, brain MRI showed symmetric T2-
hyperintense alterations localized in the globi pallidi and
the posterior part of the putamina, reminiscent of Leigh-
like lesions. A mild atrophy of cerebellar vermis was also
present (Fig. 1B). MR spectroscopy analysis of the lentic-
ular lesions revealed a reduction of the N-acetylaspartate
(NAA) peak, an increased lactic acid peak, and the pres-
ence of a 0.9-ppm peak, corresponding to elevated BCAAs
Valine, Leucine and Isoleucine (Fig. 1C).
Electroencephalography (EEG) showed bilateral recur-
rent bursts of sharp waves in Subject II-3. EEG back-
ground was well-formed. Electromyography (EMG) and
nerve conduction studies (NCS) displayed chronic myo-
genic changes in Subject II-1. Motor evoked potentials
(MEPs) demonstrated a moderate slowing of the central
conduction velocity in both the upper and lower limbs in
Subject II-3. MEPs were suggestive of corticospinal tract
dysfunction. Indeed, the increased muscular tone was
attributed to a combination of dystonia and spasticity.
Muscle biopsies of the left biceps brachii, performed in
both siblings, showed only few COX-negative fibers in
Subject II-1. No cardiological abnormalities were found
(electrocardiography and echocardiography). Serum lactic
acid was mildly increased. Urine organic acid profiles
were normal. Ocular fundus examination was normal.
Experimental methods are described in Supplementary
Data.
RESULTS
Exome scans in the affected sisters detected two missense
mutations in ECHS1 (NM_004092.4) (Figures S1 and S2).
The previously described3 c.476A> G mutation
(chr10:135,182,465T> C) results in the amino acid substi-
tution p.Q159R. The c.244G> T variant (chr10:
135,184,106C> A) is novel and produces a p.V82L change,
predicted as deleterious (Fig. 1D and Figure S3). Segrega-
tion test confirmed the recessive inheritance (Figure S4).
ECHS1 enzyme activity was spectrophotometrically
measured in cultured fibroblasts10 and found markedly
reduced in patients (mean values 253.65  107.00 pmol/
min/mg) compared to controls (546.13  36.30 pmol/
min/mg, P < 0.01, Fig. 1E). Similarly, steady-state levels of
the mitochondrial ECHS1 protein (Figure S5) were found
reduced in patients compared to controls (P < 0.01): resid-
ual protein levels were 26.5% and 8.25% in Subjects II-1
and II-3, respectively (Figure 1F and Figure S6).
No significant difference in the expression of represen-
tative mitochondrial respiratory chain subunits or the
marker of mitochondrial content PORIN was observed
(Fig. 2A and Figure S7). Immunocytochemical studies in
fibroblasts demonstrated the mitochondrial localization of
ECHS1 immunoreactivity, as determined by colocalization
Figure 1. Clinical, genetic and biochemical findings. (A) Pedigree and genotypes of the family investigated. (B) MRI scans showing symmetric T2-
hyperintense alterations localized (black arrows) in the globi pallidi (II-1 and II-3) and the posterior part of the putamina (II-3). (C) MR spectroscopy
analysis of the lenticular lesions in Subjects II-1 and II-3 showing (white arrows) an increased peak at 1.3 ppm (Lactate) and the presence of a
0.9 ppm peak (BCAA). (D) Electropherogram showing the ECHS1 nucleotide substitutions detected in our patients and resulting in conserved
amino acid changes. (E) Biochemical analysis of Enoyl-coA hydratase activities in patients’ and control (n = 4) fibroblasts. Values are expressed as
pmol/min/mg after normalization to citrate synthase activity and presented as mean  standard deviation (three replicates, **P < 0.05). (F)
Western Blot analysis of ECHS1 protein signals normalized to ACTIN in patients and control fibroblasts. Values are expressed as arbitrary units
(a.u.) and presented as mean  standard deviation of three independent experiments (**P < 0.05).
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with TOMM20, and confirmed the reduction of ECHS1
expression in the two patients. TOMM20 staining did not
display alterations in the distribution of mitochondria
(Fig. 2B). The evaluation of mitochondrial membrane
potential showed slight changes in ECHS1-mutated cells
(Fig. 2C and Figure S8). Red-oil staining of patients’
cells11 did not display lipid accumulation (Fig. 2D and
Figure S9), reflecting the negative results of muscle biopsy
(not shown).
The expression of apoptotic markers BAX and cleaved
PARP1 was unchanged in mutated and control fibroblasts,
even after L-valine supplementation (Fig. 2E). The experi-
ment was repeated in human neuroblastoma SHSY5Y cells
after ECHS1-downregulation obtained by transient RNA
interference and confirmed at protein level (30% compared
to mock-transfected cells) (Fig. 2F). In ECHS1-silenced
neuronal cells, activation of apoptosis was suggested by the
detection of cleaved PARP1 and Caspase 3 forms before
and after L-valine supplementation (Fig. 2G),
DISCUSSION
We described two siblings with ECHS1-deficiency associ-
ated with a novel dystonia-ataxia syndrome allowing sur-
vival into adulthood. Besides bilateral hearing loss, our
patients also showed an impressive rotatory nystagmus
and, in the older sister, a severe muscle hypotrophy. Car-
diac and optic nerve involvement were ruled out.
To our knowledge, our patients are the most long-living
ECHS1-mutated subjects reported so far. Heterogenous
clinical presentations are not uncommon in primary
mitochondrial diseases, even in the presence of the same
genotype. The p.Q159R has been previously described in
either the homozygous or compound heterozygous state in
clinically affected patients mainly showing LLS with early-
infancy onset and premature death.12 Haack and co-au-
thors described a 31-year old woman with spastic tetra-
paresis who had lost deambulation at the age of 9.5.
Additional clinical symptoms included optic atrophy,
developmental delay, epilepsy and hearing loss. The second
allele showed a missense mutation at codon 77 which
allowed a partial conservation of ECHS1 activity.3 In our
probands, the second mutation is located nearby (codon
82) and residual protein and activity levels are overall
higher compared to severe pediatric presentations. The
review of published cases for which residual ECHS1 activity
levels in fibroblasts were available2-3,9,13-15 suggests a posi-
tive correlation between enzyme activity and survival (Fig-
ure S10, Pearson’s correlation coefficient r = 0.88,
P < 0.05). These observations are meaningful for prognosis
and the identification of biochemical thresholds to monitor
experimental therapies aiming to rescue ECHS1 activity.
Increased levels of serum pyruvate, lactate and Krebs
cycle metabolites point to a deficit in energy metabolism,
but these unspecific findings are not consistently observed
in all ECHS1-mutated patients, including ours. We failed
to observe clear evidences of mitochondrial respiratory
chain dysfunction which is limited to the presence of few
COX-negative fibers in the muscle of the elder sister. Sim-
ilarly, no accumulation of lipids was found at the tissue
and cellular levels. Therefore, ECHS1-mutated fibroblasts
did not show prominent alterations of mitochondrial res-
piratory chain or fatty acids catabolism, exculpating these
pathways as the main pathogenetic drivers of ECHS1 defi-
ciency.
A positive MRI scan with basal ganglia involvement
has been documented in all the presentations due to
ECHS1 mutations, despite clinical symptoms and course,
not differently from other disorders featuring Leigh or
Leigh-like syndromes. Brain spectroscopy was more speci-
fic and disclosed in both of our patients a peak corre-
sponding to BCAA. Therefore, brain spectroscopy could
be used to accelerate diagnosis and to validate genetic
findings in additional patients for which biochemical
investigations are negative or unavailable.
The elucidation of the pathogenetic cascade originating
from ECHS1-deficiency is important for the design of
therapies. For example, ROS scavenging might be ineffec-
tive if respiratory chain dysfunction is a secondary event,
while dietary restrictions to limit BCAA intake could have
Figure 2. Immunocytochemical and protein studies in cellular models of ECHS1 deficiency. (A) Western Blot analysis of representative subunits of
mitochondrial respiratory chain. Histograms show densitometric analysis (arbitrary units, a.u.) expressed as mean  standard deviation of three
experiments. No difference was observed between patients’ and controls fibroblasts. (B) Immunocytochemical studies addressing mitochondrial
content and localization (TOMM20, green) supported the mitochondrial localization of ECHS1 and did not show any clear difference between
patient’s and controls fibroblasts. (C) JC1 staining of free cytoplasmic aggregates (green) in patients’ fibroblasts indicative of mild dissipation of
mitochondrial membrane potential. (D) Oil Red O (ORO) staining to detect intracellular lipids (cytosolic red dots) did not show any difference
between patients and controls cells in basal conditions or after supplementation of L-Valine in culture medium (5 and 50 mmol/L for 24 h). (E)
Representative Western blot analysis of apoptotic markers PARP1, Bcl2 and BAX in fibroblasts of Subjects II-3 and healthy controls in basal
condition or after L-Valine supplementation (50 mmol/L, 24 h). Actin was used as a loading control. (F) Downregulation of ECHS1 expression in
SHSY5Y after siRNA-based interference for 48 hours compared to mock-transfected condition (two replicates, **P < 0.05). (G) Representative
Western blot analysis of total and cleaved (cl-) apoptotic markers PARP1 and CASP3 in mock-transfected or silenced (siRNA ECHS1) SHSY5Y cells.
Histograms show densitometric analysis (arbitrary units) expressed as mean  standard deviation of three experiments (**P < 0.05) performed in
basal conditions or after L-Valine supplementation (50 mmol/L, 24 h). ACTIN was used as a loading control.
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minimal effects on BCAA accumulation in the central
nervous system.16 In this regard, we observed the activa-
tion of programed cellular death only when ECHS1 defi-
ciency was experimentally achieved in a neuronal model.
Further studies in patient-specific neuronal cells are
mandatory to explore the mechanisms underlining the
cell-type selectivity of ECHS1 deficiency.
The overlapping clinical features observed in our
patients and in two subjects harboring mutations in
HIBCH, the enzyme acting downstream ECHS1 in valine
catabolism, suggest a key role for BCAA metabolism in
brain biochemistry.17 Indeed, ECHS1 has been recently
proposed as an intracellular sensor of nutrients able to
influence mammalian target of Rapamycin (mTOR) sig-
naling and apoptosis.18 These findings refocus ECHS1-de-
ficiency, and the consequent increase of BCAA levels, in
the context of global intracellular metabolism. Pharmaco-
logical manipulation of mTOR might alleviate the meta-
bolic effects of ECHS1-deficiency paralleling the results
obtained in other genetic forms of mitochondrial-related
neurodegeneration,19 including Leigh Syndrome.20
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